Novartis responds to ongoing corruption investigations
Novartis has issued a response concerning ongoing corruption investigations by both Greek and U.S. authorities.
Related articles
-
ArticleNovartis sets aside $700M in kickback case
Swiss pharmaceutical drug maker Novartis announced it has set aside $700 million for a potential settlement in a long-running lawsuit over allegations that the company paid hundreds of millions of dollars in kickbacks to doctors to induce them into prescribing drugs to patients to boost their sales.
-
Article
Distilling compliance lessons from Novartis
Ethics and compliance officers in the pharmaceutical industry can learn a lot from the troubles of Novartis, which faced a firestorm of criticism from shareholders at its last annual meeting.
-
News BriefDOJ secures $118 million penalty in FCPA violation case tied to Guatemalan telecom firm
The parent company of a telecom subsidiary in Guatemala agreed to pay $118.2 million to settle allegations of improper payments made to government officials, but the U.S. Department of Justice chose not to impose a compliance monitor to administer the firm’s compliance with the Foriegn Corrupt Practices Act (FCPA).